Edition:
United Kingdom

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

2.68USD
19 Sep 2018
Change (% chg)

$0.13 (+5.10%)
Prev Close
$2.55
Open
$2.56
Day's High
$2.75
Day's Low
$2.56
Volume
20,964
Avg. Vol
71,846
52-wk High
$4.04
52-wk Low
$1.80

Chart for

About

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $70.63
Shares Outstanding(Mil.): 30.11
Dividend: --
Yield (%): --

Financials

  SPHS.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -0.26 -- --
ROI: -47.03 15.07 14.61
ROE: -97.97 16.59 16.33

BRIEF-Sophiris Bio Q4 Loss Per Share $0.13

* SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS

21 Mar 2018

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥2,038 +32.00
Pfizer Inc. (PFE.N) $43.26 -0.25
Merck & Co., Inc. (MRK.N) $69.98 -0.44
Sanofi SA (SASY.PA) €75.12 --
GlaxoSmithKline plc (GSK.L) 1,496.80 +10.00
Eli Lilly And Co (LLY.N) $105.74 -1.14

Earnings vs. Estimates